(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Subjects with Helicobacter pylori infection
Subjects with known hypersensitivity to the study drug.
Subjects with a history of gastric surgery.
Subjects with severe liver cirrhosis or uremia.
Subjects with a history of malignancy within the past five years.
Parallel
vonoprazan, tripotassium dicitrate bismuthate, amoxicilline
Drugbismuth-amoxicillin-vonoprazan triple therapy
rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole
Drugbismuth-based quadruple therapy
The rate of Helicobacter pylori eradication
evaluate eradication by 13C urea breath test
Evaluation of the safety of Helicobacter pylori eradication therapy
Drug-related adverse effects assessed by a standardized questionnaire
genotype analysis
Genotype analysis (CYP3A4, CYP2C19, and IL-1B -511) will be performed using a blood sample collected once at study entry.
Click on the lead sponsor to view all of their trials.
Kaohsiung Medical University
Lead sponsor
Kaohsiung Veterans General Hospital.
Collaborator
